FDA & Government News

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Share

  • 1

    FDA expands Arexvy approval to adults 18-49 at increased risk for RSV.

  • 2

    Prior approval was only for those 60+ years and 50-59 with risk factors.

  • 3

    21 million under 50 have RSV risk factors in the US.

  • 4

    Phase 3b trial showed noninferior immune response in younger adults.

  • 5

    Common adverse events include injection site pain and fatigue.

  • 6

    RSV may exacerbate chronic conditions like COPD and asthma.

  • 7

    Vaccine has global approvals and shows safety consistency from trials.

Original Source(s)

RSV Vaccine Eligibility Expands

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Clinicians Warn of Fatal Measles Brain Disease

Doctors caution that measles infection can lead to SSPE, a rare fatal neurologic disease that may appear years later.

The New Blueprint for Vaccine Development

ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness

  • March 12, 2026

  • 6 min
The 60 Percent Diagnostic Gap in M/E

What earlier mNGS testing could mean for labs and clinicians